Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Simard

Showing results (61-70 of 290) with videos related to

Pageof 29
Sort By:
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 7, 2021
Potential of polygenic risk scores for improving population estimates of women's breast cancer genetic risksMichael Wolfson, Steve Gribble, Nora Pashayan, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 28, 2016
Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk modelAndrew J Lee, Alex P Cunningham, Marc Tischkowitz, et al.
Biochimica Et Biophysica Acta|September 11, 2004
Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2Martine Dumont, David Frank, Anne-Marie Moisan, et al.
The Journal of Steroid Biochemistry and Molecular Biology|November 14, 2002
Glucocorticoids enhance activation of the human type II 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase geneF Alex Feltus, Stephanie Cote, Jacques Simard, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 26, 2016
Inherited Chromosomally Integrated Human Herpesvirus 6 and Breast CancerAnnie Gravel, Isabelle Dubuc, Angela Brooks-Wilson, et al.
Journal of the National Cancer Institute|December 12, 2024
Evaluating the performance of the Breast and Ovarian Analysis of Disease Incidence Algorithm model in predicting 10-year breast cancer risks in UK BiobankCarmen Petitjean, Naomi Wilcox, Lorenzo Ficorella, et al.
European Journal of Human Genetics : EJHG|January 21, 2011
Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and QuebecMichel Dorval, Catherine Noguès, Pascaline Berthet, et al.
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC|March 10, 2007
Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutationDoug Horsman, Brenda J Wilson, Denise Avard, et al.
Current Oncology (Toronto, Ont.)|November 10, 2022
Using Real-World Data to Determine Health System Costs of Ontario Women Screened for Breast CancerNicole Mittmann, Soo Jin Seung, Christina Diong, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|June 23, 2005
Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitutionSylvain Gauthier, Julie Cloutier, Yves L Dory, et al.
Pageof 29

Showing results (61-70 of 290) with videos related to

Sort By:
Pageof 29
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 7, 2021
Potential of polygenic risk scores for improving population estimates of women's breast cancer genetic risksMichael Wolfson, Steve Gribble, Nora Pashayan, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 28, 2016
Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk modelAndrew J Lee, Alex P Cunningham, Marc Tischkowitz, et al.
Biochimica Et Biophysica Acta|September 11, 2004
Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2Martine Dumont, David Frank, Anne-Marie Moisan, et al.
The Journal of Steroid Biochemistry and Molecular Biology|November 14, 2002
Glucocorticoids enhance activation of the human type II 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase geneF Alex Feltus, Stephanie Cote, Jacques Simard, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 26, 2016
Inherited Chromosomally Integrated Human Herpesvirus 6 and Breast CancerAnnie Gravel, Isabelle Dubuc, Angela Brooks-Wilson, et al.
Journal of the National Cancer Institute|December 12, 2024
Evaluating the performance of the Breast and Ovarian Analysis of Disease Incidence Algorithm model in predicting 10-year breast cancer risks in UK BiobankCarmen Petitjean, Naomi Wilcox, Lorenzo Ficorella, et al.
European Journal of Human Genetics : EJHG|January 21, 2011
Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and QuebecMichel Dorval, Catherine Noguès, Pascaline Berthet, et al.
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC|March 10, 2007
Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutationDoug Horsman, Brenda J Wilson, Denise Avard, et al.
Current Oncology (Toronto, Ont.)|November 10, 2022
Using Real-World Data to Determine Health System Costs of Ontario Women Screened for Breast CancerNicole Mittmann, Soo Jin Seung, Christina Diong, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|June 23, 2005
Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitutionSylvain Gauthier, Julie Cloutier, Yves L Dory, et al.
Pageof 29